Researchers at Scripps Research Institute have developed a new drug, diAcCA, from carnosic acid, which is found in rosemary and sage. This innovative compound significantly lowers inflammation in the brains of mice, a critical factor in Alzheimer's disease. Not only does diAcCA mitigate inflammation, but it also restores the number of nerve cell connections vital for cognitive functions like learning and memory. Since carnosic acid is considered safe by the FDA, there are hopes to expedite its clinical trials, allowing for faster access to Alzheimer’s patients. The targeted action of diAcCA further minimizes potential side effects, a common issue with current medications.
Carnosic acid, found in rosemary and sage, has shown promise in potentially reversing Alzheimer’s disease by reducing inflammation in the brain.
The new treatment diAcCA not only extinguished inflammation but also restored nerve cell connections critical for learning and memory.
With carnosic acid deemed safe by the FDA, there is optimism for fast-tracked clinical trials that could bring relief to Alzheimer’s patients.
The innovative drug diAcCA activates specifically in inflamed regions of the brain, limiting side effects typically encountered with other medications.
Collection
[
|
...
]